The FDA has granted approval for a new medication named SIMTRIYO to treat attention deficit hyperactivity disorder in children aged 6 and older and adults. Developed by Otsuka Pharmaceutical, this medication utilizes centanafadine as its active ingredient. It is classified as a norepinephrine, dopamine, and serotonin reuptake inhibitor, which differentiates it from existing stimulant and nonstimulant options currently available on the market.
Clinical evidence supporting this approval includes four phase 3 trials covering adults, adolescents, and children. Participants who received the medication showed improvements in ADHD symptoms compared to those who received a placebo. A phase 3b study also indicated positive outcomes for adults managing both ADHD and comorbid anxiety. While the results appear promising, the drug comes with a boxed label warning regarding risks of suicidal ideation, potential for abuse, and misuse. Common side effects reported during the trials include decreased appetite, nausea, and headache.
Healthcare providers view this development as an additional tool for patients who have not experienced success with conventional treatments. Dr. Daniel Ganjian, a pediatrician, noted that he intends to use it for patients who require alternatives when current methods fall short. Similarly, Dr. Max Wiznitzer of Case Western Reserve University emphasized that while medication provides a starting point for managing symptoms, behavioral therapy remains an essential component for long-term success.
Before the drug reaches patients, the Drug Enforcement Administration must complete hearings to determine its specific scheduling classification. Otsuka Pharmaceutical anticipates that the medication will be available for prescription later this year. Experts continue to highlight that ADHD remains a highly individualized condition, and treatment plans often require a mix of medication, organization strategies, and behavioral support to address the full scope of a patient’s life.